Obesity and outcome in pediatric acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 25, Issue 15, 2007, Pages 2063-2069

  Butturini, Anna M ^a   Dorey, Frederick J ^b   Lange, Beverly J ^b   Henry, David W ^b   Gaynon, Paul S ^b   Fu, Cecilia ^b   Franklin, Janet ^b   Siegel, Stuart E ^b   Seibel, Nita L ^b   Rogers, Paul C ^b   Sather, Harland ^b   Trigg, Michael ^b   Bleyer, W Archie ^b   Carroll, William L ^b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BODY MASS; BODY SURFACE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; PANCREAS DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE LYMPHOCYTIC LEUKEMIA; COHORT ANALYSIS; DISEASE FREE SURVIVAL; PATHOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; OBESITY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34249935177     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.7792     Document Type: Article

References (30)

1. Hedley AA, Ogden CL, Johnson CL, et al: Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291:2847-2850, 2004
2. Calle EE, Kaaks R: Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579-591, 2004
3. Krebs NF, Jacobson MS: Prevention of pediatric overweight and obesity. Pediatrics 12:424-430, 2003
4. Hutchinson RJ, Gaynon PS, Sather H, et al: Intensification of therapy for children with low risk acute lymphoblastic leukemia: Long term follow up of patients treated on Children's Cancer Group Trial 1881. J Clin Oncol 21:1790-1797, 2003
5. Bostrom BC, Sensel MR, Sather H, et al: Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patient with standard-risk acute lymphoblastic leukemia: A report from Children's Cancer Group. Blood 101:3809-3817, 2003
6. Lange BJ, Bostrom BC, Cherlow JM, et al: Double delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: A report from Children's Cancer Group. Blood 99:825-833, 2002
7. Nachman J, Sather H, Cherlow JM, et al: Response of children with high risk acute lymphoblastic leukemia treated with or without cranial irradiation: A report from Children's Cancer Group. J Clin Oncol 16:920-930, 1998
8. Nachman J, Sather H, Sensel MR, et al: Augmented post induction therapy for children with high risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338:1663-1671, 1998
9. Heath JA, Steinherz P, Alman A, et al: Human granulocyte colony stimulating factor in children with high risk acute lymphoblastic leukemia: A report from Children's Cancer Group. J Clin Oncol 21:1612-1617, 2003
10. Seibel NL, Steinherz P, Sather H, et al: Early treatment intensification improves outcome in children and adolescents with acute lymphoblastic leukemia presenting with unfavorable features who show a rapid early response to induction chemotherapy: A report of CCG 1961. Blood 102:224a, 2003 (abstr)
11. Gaynon PS, Bostrom BC, Hutchinson R, et al: Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies. J Clin Oncol 19:1916-1925, 2001
12. Carroll WL: Race and outcome in childhood acute lymphoblastic leukemia. JAMA 290:2061-2063, 2003
13. Warner JT, Cowan FJ, Dunstan FD, et al: The validity of body mass index for the assessment of adiposity in children with disease states. Ann Hum Biol 24:209-215, 1997
14. Butturini A, Vignetti M, Gubbiotti S, et al: Obesity independently affects event free survival (EFS) in adults with BCR-ABL-negative acute lymphoblastic leukemia (ALL): A retrospective analysis of two GIMEMA studies. Blood 106:520a, 2005 (abstr)
15. Lange BJ, Gerbing RB, Feusner J, et al: Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 293:203-211, 2005
16. Meloni G, Proia A, Capria S, et al: Obesity and autologous stem cell transplantation in acute myeloid leukemia. Bone Marrow Transplant 28:365-367, 2001
17. Colleoni M, Li S, Gelber RD, et al: Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet 366:1108-1110, 2005
18. Meyerhardt JA, Tepper JE, Niedzwiecki D, et al: Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: Findings from Intergroup Trial 0114. J Clin Oncol 22:648-657, 2004
19. Zuccaro P, Guandalini S, Pacifici R, et al: Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. Ther Drug Monit 13:37-41, 1991
20. Veal GJ, Cole M, Errington J: Pharmacokinetics of dactinomycin in a pediatric patient population: A United Kingdom Children's Cancer Group Study. Clin Cancer Res 11:5895-5899, 2005
21. Berg SL, Bomgaars L, Twist C, et al: Impact of body composition on pharmacokinetics of doxorubicin in pediatric patients: A Glass Pediatric Research Network study. J Clin Oncol 23:804s, 2005 (suppl; abstr 8519)
22. Cheymol G: Effect of obesity on pharmacokinetics. Clin Pharmacokinet 39:215-231, 2000
23. Ngo TH, Barnard RJ, Leung PS, et al: Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: Possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 144:2319-2324, 2003
24. Onuma M, Bub JD, Rummel TL, et al: Prostate cancer cell-adipocyte interaction: Leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 278:42660-42667, 2003
25. Furukawa S, Fujita T, Shimabukuro M, et al: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752-1761, 2004
26. Brakenhielm E, Veitonmaki N, Cao R, et al: Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 101:2476-2481, 2004
27. Fukuhara A, Matsuda M, Nishizawa M, et al: Visfatin: A protein secreted by visceral fat that mimics the effect of insulin. Science 305:426-430, 2005
28. Wilson WA, Roach PJ: Nutrient-regulated protein kinases in budding yeast. Cell 111:155-158, 2002
29. Goodwin PJ, Ennis M, Pritchard KI, et al: Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J Clin Oncol 20:42-51, 2002
30. Weiser MA, Cabanillas ME, Konopleva M, et al: Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 100:1179-1185, 2004